Activity Overview
Research revealing that overexpression of TL1A drives key pathological pathways in inflammatory bowel disease (IBD) has accelerated the development of biologic therapies aimed at inhibiting this ligand. Early studies of investigational anti-TL1A agents—including tulisokibart, afimkibart, and duvakitug—demonstrate encouraging outcomes in patients with moderate to severe IBD, showing improvements in symptoms and reductions in chronic intestinal inflammation and fibrosis. In this fast-moving area, education tailored to gastroenterology-focused clinicians who are navigating an increasingly dynamic IBD treatment landscape is needed. This activity explores emerging evidence and potential clinical applications of TL1A inhibitors. Through case-based discussions and interactive polling, participants will gain practical, up-to-date strategies to enhance IBD management and remain at the forefront of therapeutic innovation.
This educational activity is an archive of the live virtual symposium held on January 23, 2026.
Target Audience
This program is directed towards gastroenterologists, nurse practitioners, physician assistants, internists, nurses, and other health care practitioners who manage patients with IBD.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the limitations of currently approved advanced targeted drugs in achieving STRIDE II goals for patients with UC or CD
- Describe the role TL1A plays in the inflammatory pathophysiology of UC and CD
- Explain the mechanism of action of TL1A inhibitors in the management of UC and CD
- Evaluate clinical trial efficacy and safety data for anti-TL1A agents in the management of patients with UC or CD
Jordan Axelrad, MD, MPH, FACG, FCCF
NYU Grossman School of Medicine
New York, NY
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Abvax, Adiso, bioMérieux, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Fresenius, Janssen, Merck, Sanofi, Pfizer, Takeda, and Vedanta; Grant/Research Funding: BioFire Diagnostics, Genentech, Janssen, and Takeda
Jessica R. Allegretti, MD, MPH
Brigham and Women’s Hospital
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Bristol Myers Squibb, Celltrion, Curogen, Ferring, Genentech, GSK, Janssen, Merck, Metagen, Pfizer, Roivant, Seres Therapeutics, Shattuck Labs, TRexBio, Vedanta, Xencor
Florian Rieder, MD
Cleveland Clinic
Cleveland, OH
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Abivax, Adiso, Adnovate, Agomab, Allakos, Allergan, Anaptys, Arena, AstraZeneca, Bausch & Lomb, Boehringer Ingelheim, Cabaletta, Cage, Cellarity, Celgene/Bristol Myers Squibb, CDISC, Celltrion, Celsius, Chemomab, Cowen, 89Bio, Enveda, Equillium, Eugit, Falk, Ferring, Frequency Therapeutics, Galapagos, Galmed, Genentech, Gilead, Gossamer, Granite, GSK, Guidepoint, Helios, Helmsley, Horizon Therapeutics, Image Analysis Limited, IMIDomics, Index Pharma, Janssen, Koutif, Landos, Lassen, Lilly, Medibiofarma, Merck, Mestag, Metacrine, Mirador, Mirum, Mobius, Mopac, Morphic, Myka Labs, Nxera, Ono, Organovo, Origo, Palisade, Pfizer, Pharvaris, Pliant, Prometheus Biosciences, Receptos, Redx, Roche, Samsung, Sanofi, Sironax, SRT, SurModics, Surrozen, Takeda, Techlab, Tentarix, Teva, Thabor, Theravance, Thetis, Tillotts, Tr1X Bio, UCB, Ventus, Versant, Viatris, Virgo, Xencor, Ysios
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
